Non-invasive urine-based diagnostic test for prostate cancer screening that analyzes PSA N-glycomic alterations using recombinant antibody technology. Reduces false positives, requires no specialized operator training, and provides risk stratification for clinical decision-making. Designed for cost-...
Manufactured by
Veszprém, Hungary
iPASy is revolutionizing prostate cancer screening with a urine-based, non-invasive diagnostic that detects disease-specific glycan patterns of urinary PSA, offering up to six-times higher specificity than blood-based tests. Our vision is to make prostate cancer detection accurate, accessible, and patient-friendly worldwide , with upcoming launches in Europe and the U.S. in collaboration with Mayo Clinic .
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Glycanostics, s.r.o.
Slovakia · 5 relevant products
Biomerica, Inc.
United States · 2 relevant products
Boditech Med Inc.
South Korea · 2 relevant products
Berkeley Health Ltd
United Kingdom · 3 relevant products
Labcorp
United States · 2 relevant products
MedLevensohn
Brazil · 2 relevant products
Rayto Life and Analytical Sciences Co., Ltd.
China · 1 relevant product
Monobind Inc.
United States · 1 relevant product
Siemens Healthineers Ltd.
China · 1 relevant product
BiosPacific
United States · 1 relevant product
66 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →12 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 98 closest product alternatives
Glycanostics, s.r.o. · Slovakia
Early-stage prostate cancer diagnostic test utilizing advanced glycan analysis for highly accurate detection. Designed to identify prostate cancer at initial stages, enabling timely clinical intervention and improved patient outcomes.
Biomerica, Inc. · United States
An advanced diagnostic test for prostate cancer screening. Designed as an at-home screening product targeting high-prevalence cancer detection.
Boditech Med Inc. · South Korea
A diagnostic test reagent for screening prostate cancer and monitoring the effects of treatment.
Berkeley Health Ltd · United Kingdom
Rapid self-test kit for prostate PSA screening enabling home-based detection and early identification of prostate health concerns. The test delivers accurate results comparable to clinical laboratory analysis with simple instructions and quick turnaround. ISO 13485:2016 certified in-vitro diagnostic device designed for patient convenience and accessibility.
Boditech Med Inc. · South Korea
A diagnostic test reagent for screening prostate cancer, monitoring treatment effectiveness, assessing risk, and detecting recurrence.
Glycanostics, s.r.o. · Slovakia
A non-invasive liquid biopsy diagnostic test for early-stage prostate cancer detection based on glycan analysis in blood serum. The test uses antibody-coated magnetic particles to detect cancer biomarkers from a minimal blood sample (10 µL or less than a single blood drop) with up to 90% accuracy. It is organ-specific, compatible with standard ELISA-based equipment and automated diagnostic systems, and designed to separate healthy men from those at risk of prostate cancer who require confirmatory biopsy, thereby reducing unnecessary biopsies.
Glycanostics, s.r.o. · Slovakia
Non-invasive liquid biopsy test for early-stage prostate cancer detection using glycan analysis in blood serum. Achieves up to 90% accuracy using magnetic particle-based technology with minimal blood sample requirement of 10 microliters.
Labcorp · United States
Blood test measuring prostate-specific antigen for prostate cancer risk assessment. Supports early detection and monitoring of prostate health in men.
MedLevensohn · Brazil
A rapid diagnostic test for prostate cancer screening. The test enables early detection of prostate-specific antigen (PSA) levels, with early diagnosis shown to increase cure rates up to 90%.
Rayto Life and Analytical Sciences Co., Ltd. · China
Immunoassay for PSA measurement in prostate cancer screening and monitoring. Supports clinical decision-making in urology.
Monobind Inc. · United States
Immunoassay tests for prostate-specific antigen detection in patient samples. These products support prostate cancer screening and monitoring.
Berkeley Health Ltd · United Kingdom
Rapid home test kit for semi-quantitative detection of prostate-specific antigen in human whole blood. Enables self-screening for prostate health status with results available within 15 minutes. ISO 13485:2016 certified for accuracy and reliability.
86 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products